The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue 1, 2011, Pages 65-74

  Metharom, Ekkaphon ^a,c   Galettis, Peter ^a,c   Manners, Susan ^a   Jelinek, Maria ^d   Liauw, Winston ^a,c   De Souza, Paul L ^a,b,c   Hoskins, Janelle M ^e   Links, Matthew ^a,c,d  

^a Cancer Pharmacology Therapeutics Group   (Australia)

^b St George and Sutherland Hospitals   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ST GEORGE HOSPITAL   (Australia)

^e SYDNEY CANCER CENTRE   (Australia)

Author keywords

Gemcitabine; Pharmacodynamics; Pharmacogenetics; Pharmacokinetics; Predictive

Indexed keywords

CYTIDINE DEAMINASE; GEMCITABINE; GENOMIC DNA;

ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DNA SEQUENCE; DOSAGE SCHEDULE COMPARISON; DRUG INFUSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKEMIA; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPY DELAY; UNIVARIATE ANALYSIS;

ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; CROSS-OVER STUDIES; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 79951756139     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01354.x     Document Type: Article

References (20)

1. Abbruzzese JL, Grunewald R, Weeks EA etal. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
2. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2', 2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27: 258-62.
3. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 2004; 4: 307-14.
4. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997; 24 (2 Suppl 7):S7-2-S7-7.
5. Poplin E, Levy DE, Berlin J etal. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine+oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J of Clin Oncol ASCO Meeting Abstracts 2006; 24 (Suppl 18):LBA4004.
6. Grimison P, Galettis P, Manner S etal. A randomised crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation. J Clin Oncol 2007; 25: 5704-9.
7. Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998; 26: 421-5.
8. Giovannetti E, Laan AC, Vasile E etal. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 2008; 27: 720-5.
9. Sugiyama E, Kaniwa N, Kim SR etal. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25: 32-42.
10. Bepler G, Zheng Z, Gautam A etal. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005; 47: 183-92.
11. Shi JY, Shi ZZ, Zhang SJ etal. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 2004; 14: 759-68.
12. Gilbert JA, Salavaggione OE, Ji Y etal. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006; 12: 1794-803.
13. Kwon WS, Rha SY, Choi YH etal. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 2006; 16: 429-38.
14. Rha SY, Jeung HC, Choi YH etal. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist 2007; 12: 622-30.
15. Kim SO, Jeong JY, Kim MR etal. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 2008; 14: 3083-8.
16. Bepler G, Kusmartseva I, Sharma S etal. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4731-7.
17. Mercier C, Raynal C, Dahan L etal. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 2007; 17: 841-4.
18. Yonemori K, Ueno H, Okusaka T etal. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005; 11: 2620-4.
19. Tibaldi C, Giovannetti E, Vasile E etal. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008; 14: 1797-803.
20. Tempero M, Plunkett W, Ruiz van Haperen V etal. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402-8.